FB Pixel no scriptUS investors race to license China biotech
MENU
KrASIA
Jun
2

US investors race to license China biotech

just now
US investors are rushing to license drugs from China as the country’s biotech sector gains global clout. Nearly 30% of recent pharmaceutical licensing deals involved Chinese firms, up sharply from prior years. VCs cite competitive pricing, speed, and innovation, with companies like Pfizer and Verdiva already securing major deals.
Share

Latest Pulses

See All

Most Recent